Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC11990TCS-PIM-1-4aCAS: 327033-36-3纯度: >99.50%
TCS-PIM-1-4a (SMI-4a) 是一种泛 Pim 激酶抑制剂,通过激活 AMPK 来阻断 mTORC1 的活性。 TCS-PIM-1-4a 可杀死多种髓系和淋巴系细胞系(IC50 值范围为 0.8 μM 至 40 μM)。
- GC12136BAY 61-3606 dihydrochlorideCAS: 648903-57-5纯度: >98.00%
BAY 61-3606 dihydrochloride 是一种可口服的、ATP 竞争性、可逆和高选择性的 Syk 抑制剂,Ki 为 7.5 nM,IC50 为 10 nM。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC11985 | SC 66 | 871361-88-5 | >99.50% | |
A dual inhibitor of Akt | ||||
| GC11988 | 15-acetoxy Scirpenol | 2623-22-5 | - | |
A trichothecene mycotoxin | ||||
| GC11989 | Nortriptyline (hydrochloride) | 894-71-3 | >99.50% | |
A tricyclic antidepressant | ||||
| GC11990 | TCS-PIM-1-4a | 327033-36-3 | >99.50% | |
TCS-PIM-1-4a (SMI-4a) 是一种泛 Pim 激酶抑制剂,通过激活 AMPK 来阻断 mTORC1 的活性。 TCS-PIM-1-4a 可杀死多种髓系和淋巴系细胞系(IC50 值范围为 0.8 μM 至 40 μM)。 | ||||
| GC11993 | PAC-1 | 315183-21-2 | >98.00% | |
PAC-1是一种具有口服活性的小分子procaspase-3激活剂,可诱导癌细胞凋亡,EC 50 为2.08μM。 | ||||
| GC12003 | VR23 | 1624602-30-7 | >99.00% | |
A proteasome inhibitor | ||||
| GC12011 | P276-00 | 920113-03-7 | >98.00% | |
P276-00 (P276-00) 是一种有效的细胞周期蛋白依赖性激酶 (CDK) 抑制剂,可抑制 CDK9-cyclinT1、CDK4-cyclin D1 和 CDK1-cyclinB,IC50 分别为 20 nM、63 nM 和 79 nM。 P276-00 (P276-00) 对顺铂耐药细胞具有抗肿瘤活性。 | ||||
| GC12013 | Sodium salicylate | 54-21-7 | >99.50% | |
水杨酸钠(水杨酸钠盐)抑制环加氧酶 2(COX-2)活性,与转录因子(NF-κB)激活无关。 | ||||
| GC12045 | LY 303511 | 154447-38-8 | - | |
An inhibitor of cell proliferation | ||||
| GC12051 | Amiloride HCl dihydrate | 17440-83-4 | >98.00% | |
An Analytical Reference Standard | ||||
| GC12053 | BAM7 | 331244-89-4 | >99.00% | |
A direct activator of Bax | ||||
| GC12066 | Retinyl (Vitamin A) Palmitate | 79-81-2 | - | |
A natural form of vitamin A | ||||
| GC12070 | Ascorbic acid (Standard) | 50-81-7 | >99.50% / >98.00% | |
An electron donor | ||||
| GC12074 | BG45 | 926259-99-6 | >99.50% | |
A selective HDAC3 inhibitor | ||||
| GC12090 | Nonactin | 6833-84-7 | >95.00% | |
Nonactin是一种大环四内酯类抗生素和线粒体氧化磷酸化解偶联剂。 | ||||
| GC12094 | PHT-427 | 1191951-57-1 | >99.50% | |
An inhibitor of Akt and PDPK1 | ||||
| GC12105 | Etidronate | 2809-21-4 | >98.00% | |
A bisphosphonate bone resorption inhibitor | ||||
| GC12115 | CUDC-907 | 1339928-25-4 | >99.50% | |
CUDC 是一种口服生物可利用的小分子 PI3K 和 HDAC 双重抑制剂,作用于 PI3K α 和 HDAC1 / 2 / 3 / 10,IC50 分别为 19 nm 和 1.7 nm / 5 nm / 1.8 nm / 2.8 nm .在 WSU DLCL2 细胞中评估了双功能 HDAC 和 PI3K 抑制剂 CUDC-907 的抗肿瘤活性。 | ||||
| GC12116 | Pitavastatin Calcium | 147526-32-7 | >99.00% | |
An HMG-CoA reductase inhibitor | ||||
| GC12124 | Selonsertib (GS-4997) | 1448428-04-3 | >98.50% | |
An ASK1 inhibitor | ||||
| GC12136 | BAY 61-3606 dihydrochloride | 648903-57-5 | >98.00% | |
BAY 61-3606 dihydrochloride 是一种可口服的、ATP 竞争性、可逆和高选择性的 Syk 抑制剂,Ki 为 7.5 nM,IC50 为 10 nM。 | ||||
| GC12139 | Gambogic Acid | 2752-65-0 | - | |
Gambogic Acid 是一种细胞渗透性 caspase 激活剂和细胞凋亡诱导剂,常用于乳腺癌、肺癌和肝癌等的研究。 | ||||
| GC12178 | G-749 | 1457983-28-6 | >98.00% | |
An FLT3 kinase inhibitor | ||||
| GC12191 | LY-411575 | 209984-57-6 | >98.00% | |
A γ-secretase inhibitor | ||||
